Codelivery of DOX and siRNA by folate-biotin-quaternized starch nanoparticles for promoting synergistic suppression of human lung cancer cells

Drug Delivery

Renmin Gong¹  Suoju He¹  Kuanmin Chen¹  Song Zhang¹  Hui Wang¹  Lixia Ke¹  Ezzat H Elshazly²  Liangping Li³  Lizhen Yu⁴ 

[1] College of Life Science, Anhui Normal University, Wuhu, P R China;College of Life Science, Anhui Normal University, Wuhu, P R China;Department of Botany and Microbiology, Faculty of Science, Al Azhar University, Assiut, Egyp;College of Life Science, Anhui Normal University, Wuhu, P R China;Department of Physical Education, Anhui College of Traditional Chinese Medicine, Wuhu, P R China;College of Life Science, Anhui Normal University, Wuhu, P R China;School of Pharmacy, Wannan Medical College, Wuhu, P R China;

关键词: Folate-biotin-quaternized starch nanoparticle;    doxorubicin;    siRNA;    codelivery;    human lung cancer cell lines;   

DOI  :  10.1080/10717544.2019.1606363

来源: publisher

【 摘 要 】

In this paper, the self-assembled folate-biotin-quaternized starch nanoparticles (FBqS NPs) were used as carrier system of doxorubicin (DOX) and siRNAIGF1R for the codelivery of both into human lung adenocarcinoma cell lines (A549 cells) in vitro. The cytotoxicity, targeted ligand competition, cell proliferation inhibition, cellular uptake, endocytosis mechanism and target protein suppression of drug-loaded FBqS NPs were evaluated in detail. Compared with several other drug formulations under same condition, siRNAIGF1R/DOX/FBqS NPs exhibited the greatest cytotoxicity to A549 cells and the cytotoxicity was competitively inhibited by free folate in dose-dependent manner. The A549 cells treated by siRNAIGF1R/DOX/FBqS NPs showed the lowest cell proliferation capacity. The energy-dependent clathrin- and caveolae-mediated endocytosis might be the primary cellular uptake mechanism of drug-loaded FBqS NPs. The expression of IGF1R protein in A549 cells treated by siRNAIGF1R/FBqS NPs declined dramatically. So the FBqS NPs were expected as the co-carrier system of chemotherapeutants and siRNAs for future clinical application.

【 授权许可】

CC BY